US-based women’s health medical devices company Caldera Medical has acquired UVision 360, which develops the Luminelle family of hysteroscopy and cystoscopy systems.
The Luminelle platform features high-resolution optics and a user-friendly design and provides a cost-effective solution for both diagnostic and therapeutic hysteroscopy.
Its integration with existing surgical workflows will allow gynaecologic surgeons who prioritise minimally invasive procedures, to enhance procedural accuracy and expedite patient recovery.
Caldera Medical said the strategic acquisition of UVision 360 enhances its offerings in minimally invasive solutions, particularly in advanced hysteroscopy.
Also, the acquisition widens its portfolio for diagnosing and treating conditions such as polyps, fibroids, and intrauterine pathology.
Caldera Medical CEO Bryon Merade said: “We are excited to integrate Luminelle’s technology into Caldera Medical’s growing portfolio.
“This acquisition strengthens our commitment to offering gynaecologic surgeons state-of-the-art tools that streamline hysteroscopic procedures while enhancing patient safety and clinical outcomes.”
Luminelle CEO and co-founder Allison London Brown said: “The Luminelle team has worked diligently to finally provide an accurate and easy diagnosis to a growing deadly disease, Uterine Cancer.”
UVision 360 is a medical technology company that designs and develops advanced, minimally invasive hysteroscopy and cystoscopy systems to enhance gynaecologic procedures.
Its Luminelle system offers high-quality visualisation and a simplified workflow, allowing physicians to deliver superior care in both clinical and surgical settings.
The combination of Caldera Medical’s Benesta product line with the Luminelle system offers enhanced procedural capabilities for gynecologic surgeons.
Also, it improves clinical outcomes for a wide range of intrauterine treatments, including polypectomies, biopsies, and fibroid resections in both office-based and surgical environments.
UVision360 co-founder and engineer behind Luminelle technology, Erich Dreyer said: “I’m thrilled to join the talented team at Caldera Medical to expand the commercial reach of the Luminelle portfolio.
“I’m particularly excited about our new Luminelle Bx product, which allows physicians to achieve a more accurate and precise diagnosis through its novel on-demand biopsy technology with integrated visualisation.
“With Caldera’s commercial infrastructure and investment in women’s health, we will be able to provide both physicians and patients with a solution to the flawed uterine disease diagnosis market dominated by inaccurate blind biopsies.”
